UDG.L Regulatory News (UDG)

UDG Healthcare plc

Board Appointment & Directorate Changes

3 July 2018: UDG Healthcare plc (the "Company"), a leading international healthcare services provider, is pleased to announce the appointment of Mr Erik Van Snippenberg as a Non-Executive Director of the Company with effect from 2 July 2018.

Erik spent almost thirty years at GlaxoSmithKline ("GSK") where he held a number of senior executive roles in GSK's global pharmaceutical business. Most recently, Erik held the position of SVP & Area Head for Europe and Canada and was a member of GSK's Global Pharmaceutical Management Team, Prior to this, Erik held a number of Director and General Manager roles in Europe, including SVP & Director of UK & Ireland and SVP & Director of North and West Europe.

In addition to his deep industry experience, Erik has extensive experience in product launches, product lifecycle management, business development and strategy. Erik will also join the Audit Committee with effect from 2 July 2018.

Separately, the Company also announces that Chris Corbin has decided to bring forward his retirement date as Executive Chairman of Ashfield to 30 June 2018.

As announced in September 2016, Mr Corbin was due to retire as Executive Chairman of Ashfield and from the Board of the Company in April 2019. However, at the request of the Company, Mr Corbin has agreed to extend his term on the Board in a Non-Executive Director capacity, subject to re-election at the Company's Annual General Meeting.

Commenting on the announcements, Peter Gray, Chairman of UDG Healthcare plc, said: "We are delighted that Erik has agreed to join the Board. His strong European industry and management experience will be a great asset as we continue to develop the UDG Healthcare business internationally.

We are also delighted to retain Chris Corbin as a Non-Executive director of UDG Healthcare. His deep experience and entrepreneurial spirit continues to be hugely valued by the Board."

This announcement is made in accordance with Listing Rule 9.6.11 and there is no further information to be disclosed pursuant to Listing Rule 9.6.13.

For further information, please contact:

About UDG Healthcare plc

UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering advisory, communication, commercial, clinical and packaging services to the healthcare industry, employing 9,000 people with operations in 24 countries and delivering services in over 50 countries.

UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.

Ashfield - Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three broad areas of activity: advisory, communications and commercial & clinical services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.

Sharp - Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state-of-the-art facilities in the US and Europe.

Aquilant - Aquilant is a leading distributor of specialist medical and scientific products, providing outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK and Ireland.

The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.

For more information, please go to: www.udghealthcare.com.